Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts

J. A. Hamilton, S. Lingelbach, Nicola Partridge, T. J. Martin

Research output: Contribution to journalArticle

Abstract

The plasminogen activator (PA) activity of clonal rat osteogenic sarcoma cell (phenotypically osteoblast) and of osteoblast-rich rat calvarial cells is shown to be increased by treatment with the bone-resorbing hormones, PTH, 1,25-dihydroxyvitamin D3, prostaglandin E2, and epidermal growth factor. Dose-dependent increases were observed, after a lag period of 4 to 8 h. Stimulated and control PA activities were inhibited by actinomycin D and cycloheximide but not by cytosine arabinoside. Glucocorticoid hormones prevented the hormone stimulation, but other steroids did not. Calcitonin had no effect either on basal or on hormone-treated PA activity. Isobutyl-methylxanthine alone increased PA activity and enhanced responsiveness to PTH and to prostaglandin E2. These data point to a common pathway in the actions upon osteoblasts of several hormones with diverse initial cellular actions and raise the possibility that the PA/plasmin system may contribute to cellular mechanisms of bone turnover.

Original languageEnglish (US)
Pages (from-to)2186-2191
Number of pages6
JournalEndocrinology
Volume116
Issue number6
StatePublished - 1985

Fingerprint

Plasminogen Activators
Osteoblasts
Hormones
Bone and Bones
Dinoprostone
Calcitriol
Bone Remodeling
Fibrinolysin
Cytarabine
Calcitonin
Dactinomycin
Osteosarcoma
Cycloheximide
Epidermal Growth Factor
Glucocorticoids
Steroids

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts. / Hamilton, J. A.; Lingelbach, S.; Partridge, Nicola; Martin, T. J.

In: Endocrinology, Vol. 116, No. 6, 1985, p. 2186-2191.

Research output: Contribution to journalArticle

Hamilton, J. A. ; Lingelbach, S. ; Partridge, Nicola ; Martin, T. J. / Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts. In: Endocrinology. 1985 ; Vol. 116, No. 6. pp. 2186-2191.
@article{0f5437ebc253438999eb2916907347db,
title = "Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts",
abstract = "The plasminogen activator (PA) activity of clonal rat osteogenic sarcoma cell (phenotypically osteoblast) and of osteoblast-rich rat calvarial cells is shown to be increased by treatment with the bone-resorbing hormones, PTH, 1,25-dihydroxyvitamin D3, prostaglandin E2, and epidermal growth factor. Dose-dependent increases were observed, after a lag period of 4 to 8 h. Stimulated and control PA activities were inhibited by actinomycin D and cycloheximide but not by cytosine arabinoside. Glucocorticoid hormones prevented the hormone stimulation, but other steroids did not. Calcitonin had no effect either on basal or on hormone-treated PA activity. Isobutyl-methylxanthine alone increased PA activity and enhanced responsiveness to PTH and to prostaglandin E2. These data point to a common pathway in the actions upon osteoblasts of several hormones with diverse initial cellular actions and raise the possibility that the PA/plasmin system may contribute to cellular mechanisms of bone turnover.",
author = "Hamilton, {J. A.} and S. Lingelbach and Nicola Partridge and Martin, {T. J.}",
year = "1985",
language = "English (US)",
volume = "116",
pages = "2186--2191",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts

AU - Hamilton, J. A.

AU - Lingelbach, S.

AU - Partridge, Nicola

AU - Martin, T. J.

PY - 1985

Y1 - 1985

N2 - The plasminogen activator (PA) activity of clonal rat osteogenic sarcoma cell (phenotypically osteoblast) and of osteoblast-rich rat calvarial cells is shown to be increased by treatment with the bone-resorbing hormones, PTH, 1,25-dihydroxyvitamin D3, prostaglandin E2, and epidermal growth factor. Dose-dependent increases were observed, after a lag period of 4 to 8 h. Stimulated and control PA activities were inhibited by actinomycin D and cycloheximide but not by cytosine arabinoside. Glucocorticoid hormones prevented the hormone stimulation, but other steroids did not. Calcitonin had no effect either on basal or on hormone-treated PA activity. Isobutyl-methylxanthine alone increased PA activity and enhanced responsiveness to PTH and to prostaglandin E2. These data point to a common pathway in the actions upon osteoblasts of several hormones with diverse initial cellular actions and raise the possibility that the PA/plasmin system may contribute to cellular mechanisms of bone turnover.

AB - The plasminogen activator (PA) activity of clonal rat osteogenic sarcoma cell (phenotypically osteoblast) and of osteoblast-rich rat calvarial cells is shown to be increased by treatment with the bone-resorbing hormones, PTH, 1,25-dihydroxyvitamin D3, prostaglandin E2, and epidermal growth factor. Dose-dependent increases were observed, after a lag period of 4 to 8 h. Stimulated and control PA activities were inhibited by actinomycin D and cycloheximide but not by cytosine arabinoside. Glucocorticoid hormones prevented the hormone stimulation, but other steroids did not. Calcitonin had no effect either on basal or on hormone-treated PA activity. Isobutyl-methylxanthine alone increased PA activity and enhanced responsiveness to PTH and to prostaglandin E2. These data point to a common pathway in the actions upon osteoblasts of several hormones with diverse initial cellular actions and raise the possibility that the PA/plasmin system may contribute to cellular mechanisms of bone turnover.

UR - http://www.scopus.com/inward/record.url?scp=0021906632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021906632&partnerID=8YFLogxK

M3 - Article

VL - 116

SP - 2186

EP - 2191

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -